<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727541</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-HEP-0120</org_study_id>
    <secondary_id>2020-002605-25</secondary_id>
    <secondary_id>MS200647_0075</secondary_id>
    <nct_id>NCT04727541</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer</brief_title>
  <acronym>NEOBIL</acronym>
  <official_title>Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono GmbH, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NEOBIL study aims to investigate the feasibility, safety and efficacy of neoadjuvant&#xD;
      Bintrafusp alfa in patients with resectable biliary tract cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The only curative therapy for biliary tract cancer (BTC) is resection. However, recurrence&#xD;
      rates are very high with a median recurrence-free survival (RFS) time of 18 months with&#xD;
      adjuvant chemotherapy. Bintrafusp alfa is a bifunctional fusion protein targeting TGF-β and&#xD;
      PD-L1 that has shown promising activity in a second-line phase I BTC study. The neoadjuvant&#xD;
      treatment approach is not a current standard in biliary tract cancer, but it is an accepted&#xD;
      and frequently applied treatment strategy in other resectable and borderline-resectable&#xD;
      cancers such as lung, gastric and rectal cancer. The hypothesis is that Bintrafusp alfa leads&#xD;
      to a major pathological response in 30% of resectable BTC patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Pathologic Response (MPR) measured in the surgically resected tumor</measure>
    <time_frame>24 months</time_frame>
    <description>Response to neoadjuvant treatment will be determined according to the Becker score. MPR is defined by a Becker grade of 1 (1a or 1b), namely at least &lt; 10% of viable tumor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>24 months</time_frame>
    <description>Tumor Response according to RECIST1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Resectability</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of Resectability in biliary tract cancer patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events according to CTCAE V5</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events of Special Interest</measure>
    <time_frame>24 months</time_frame>
    <description>Postoperative wound infections, impaired wound healing, wound dehiscence, prolongation of post-op hospitalization beyond 14 days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant therapy with Bintrafusp alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg of Bintrafusp alfa will be administered by intravenous infusion every 2 weeks for a total of 2 dosages (Q2W). Subsequently, the surgery will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bintrafusp alfa</intervention_name>
    <description>Neoadjuvant therapy with bintrafusp alfa</description>
    <arm_group_label>Neoadjuvant therapy with Bintrafusp alfa</arm_group_label>
    <other_name>MSB0011359C, M7824</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent granted prior to initiation of any study-specific screening&#xD;
             procedures&#xD;
&#xD;
          2. Biliary tract cancer, confirmed by histopathology, cytopathology is not sufficient&#xD;
&#xD;
          3. Resectable disease limited to the liver assessed by an interdisciplinary tumor board&#xD;
             involving a hepatobiliary surgeon; no prior systemic therapy&#xD;
&#xD;
          4. Subject is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
          5. Age ≥ 18 years&#xD;
&#xD;
          6. Performance status ECOG 0-1&#xD;
&#xD;
          7. Normal organ and bone marrow function defined as:&#xD;
&#xD;
               -  Hematopoetic: absolute neutrophil count ≥1,500/mm3, platelet count ≥ 100,000/mm3,&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  Normal international normalized ratio (INR), PT ≤ 1.5 x ULN and activated partial&#xD;
                  thromboplastin time (aPTT) ≤ 1.5 x ULN&#xD;
&#xD;
               -  Hepatic: AST ≤5 x ULN, ALT ≤ 5 x ULN, and bilirubin ≤ 3.0 x ULN.&#xD;
&#xD;
               -  Renal: Creatinine level ≤1.5 x ULN or estimated creatinine clearance ≥ 30 mL/min&#xD;
                  according to the Cockcroft-Gault formula (or local institutional standard method)&#xD;
&#xD;
          8. Special medical conditions and comorbidities:&#xD;
&#xD;
               -  Maximum Child Pugh stage A in patients with cirrhosis&#xD;
&#xD;
               -  HIV: stable on ART for at least 4 weeks, no documented evidence of multi-drug&#xD;
                  resistance, viral load of &lt; 400 copies/mL and CD4+ T-cells ≥ 350 cells/µL.&#xD;
&#xD;
               -  HBV infection: participant on a stable dose of antiviral therapy, HBV viral load&#xD;
                  below the limit of quantification.&#xD;
&#xD;
          9. Women of childbearing potential must have a negative serum or highly sensitive urine&#xD;
             pregnancy test performed within 7 days prior to the first dose of IMP.&#xD;
&#xD;
         10. Women of childbearing potential (WOCBP) must use HIGHLY EFFECTIVE method(s) of&#xD;
             contraception to avoid pregnancy for the duration of study treatment and further 2&#xD;
             months after the last dose of IMP.&#xD;
&#xD;
         11. Male participants who are sexually active with WOCBP must agree to follow instructions&#xD;
             for method(s) of contraception or to abstain from sexual activity and will be&#xD;
             instructed to adhere to either method from the time of first dose until 125 days after&#xD;
             the last dose of investigational product. In addition, male subjects must be willing&#xD;
             to refrain from sperm donation during this time. Azoospermic men do not require&#xD;
             contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastatic disease&#xD;
&#xD;
          2. Prior surgery, systemic therapy, radiation therapy, chemoradiation, transarterial&#xD;
             chemoembolisation (TACE), Radiofrequency ablation (RFA) or selective intraarterial&#xD;
             Radiotherapy (SIRT) for treatment of CCA. NOTE: Laparoscopy for diagnostic procedures&#xD;
             is allowed.&#xD;
&#xD;
          3. Drug or alcohol addiction, medical or psychological condition that may interfere with&#xD;
             the patient´s participation in the study&#xD;
&#xD;
          4. Participation in another clinical trial with any investigational study drug (whatever&#xD;
             the use, curative, prophylactic or diagnostic intent) within 30 days prior to&#xD;
             enrollment&#xD;
&#xD;
          5. Pregnancy or breast feeding women&#xD;
&#xD;
          6. Regulatory and ethical criteria:&#xD;
&#xD;
               -  Patient who has been incarcerated or involuntarily institutionalized by court&#xD;
                  order or by the authorities [§ 40 Abs. 1 S. 3 Nr. 4 AMG].&#xD;
&#xD;
               -  Patients who are unable to consent because they do not understand the nature,&#xD;
                  significance and implications of the clinical trial and therefore cannot form a&#xD;
                  rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].&#xD;
&#xD;
          7. IMMUNOSUPRESSANTS: &quot;Current use of immunosuppressive medication, EXCEPT for the&#xD;
             following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g.,&#xD;
             intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10&#xD;
             mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity&#xD;
             reactions (e.g., CT scan premedication).&quot;&#xD;
&#xD;
          8. AUTOIMMUNE DISEASE: &quot;Active autoimmune disease that might deteriorate when receiving&#xD;
             an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or&#xD;
             hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are&#xD;
             eligible.&quot;&#xD;
&#xD;
          9. PREVIOUS MALIGNANT DISEASE: within the last 3 years except for a.&#xD;
             superficial/non-invasive bladder cancer, or basal or squamous cell carcinoma in situ&#xD;
             treated with curative intent; b. endoscopically resected GI cancers limited to the&#xD;
             mucosal layer without recurrence in &gt; 1 year.&#xD;
&#xD;
         10. INFECTIONS: &quot;Active infection requiring systemic therapy. &quot;&#xD;
&#xD;
         11. VACCINATION: has received or will receive a live vaccine within 30 days prior to the&#xD;
             first administration of study intervention. Seasonal flu vaccines that do not contain&#xD;
             a live virus are permitted. Locally approved COVID vaccines are permitted.&#xD;
&#xD;
         12. HYPERSENSITIIVTY TO BINTRAFUSP ALFA: &quot;Known severe hypersensitivity [Grade ≥ 3 NCI&#xD;
             CTCAE 5.0]) to investigational product bintrafusp alfa or any component in its&#xD;
             formulations, any history of anaphylaxis, or recent, within 5 months, history of&#xD;
             uncontrollable asthma.&#xD;
&#xD;
         13. CARDIOVASCULAR DISEASE: &quot;Clinically significant (i.e., active) cardiovascular disease:&#xD;
             cerebral vascular accident/stroke (&lt; 6 months prior to enrollment), myocardial&#xD;
             infarction (&lt; 6 months prior to enrollment), unstable angina, congestive heart failure&#xD;
             (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia&#xD;
             requiring medication.&quot;&#xD;
&#xD;
         14. BLEEDING: &quot;history of bleeding diathesis or recent major bleeding events (i.e. Grade ≥&#xD;
             2 bleeding events in the month prior treatment)&#xD;
&#xD;
         15. Other severe acute or chronic medical conditions: &quot;including drug-induced interstitial&#xD;
             lung disease (ILD) or participant has had a history of drug-induced pneumonitis that&#xD;
             has required oral or IV steroids&quot;, and/or other diseases, which in the opinion of the&#xD;
             Investigator might impair the participant's tolerance for the study or ability to&#xD;
             consistently participate in study procedures.&#xD;
&#xD;
         16. Uncontrolled diabetes as defined by HbA1c &gt; 10.0 %.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Waidmann, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Frankfurt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie Worthmann</last_name>
    <phone>+49 (0) 30 8145 344</phone>
    <phone_ext>61</phone_ext>
    <email>sophie.worthmann@aio-studien-ggmbh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katrin Krause</last_name>
    <phone>+49 (0)30 8145344</phone>
    <phone_ext>32</phone_ext>
    <email>katrin.krause@aio-studien-ggmbh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum RWTH Aachen - Klinik für Allgemein-, Viszeral- und Transplantationschirurgie</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf Peter Neumann, Prof. Dr.</last_name>
      <email>uneumann@ukaachen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt - Medizinische Klinik 1</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Waidmann, Prof.Dr.</last_name>
      <email>Oliver.Waidmann@kgu.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de/</url>
    <description>AIO - Working Group for Medical Oncology from the German Cancer Society</description>
  </link>
  <link>
    <url>http://www.aio-portal.de/</url>
    <description>Description AIO-Studien-gGmbH</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

